Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
Hims & Hers falls -14.6%
Hims & Hers (HIMS) is down -14.6%, or -$3.25 to $19.00. Published first on TheFly – the ultimate source for real-time, ...
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's ...
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today released a white paper ...
Modern Healthcare9h
Telehealth firms courting employers with Ozempic, Wegovy copycats
With the cost of GLP-1s rising for employers, so-called compounded weight-loss drugs have emerged as a more cost-conscious ...
Ozempic and Wegovy considered ‘available’ after more than 2 years in shortage
The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of ...
Cautious Hold Rating for Hims & Hers Health Amid Strong GLP-1 Revenue Growth and Potential Long-term Risks
Hims & Hers Health (HIMS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Hims Says Weight-Loss Shot ‘Just as Safe’ as Ozempic and Wegovy
Hims is pushing back on the idea that compounded injections aren’t as safe or beneficial as the brand-name drugs sold by Novo and Eli Lilly & Co., even as those companies turn to the courts and the ...
bovnews2d
HIMS’s Unexpected Surge: What’s Next?
Needham has recently initiated Hims & Hers Health Inc (HIMS) stock to Buy rating, as announced on August 22, 2024, according to Finviz. Earlier, on August 9, 2024, Imperial Capital had reduced the ...